Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 216Stomach Neoplasms 166Rectal Neoplasms 146Pancreatic Neoplasms 81Colonic Neoplasms 77Neoplasm Metastasis 67Esophageal Neoplasms 55Neoplasms 31Adenocarcinoma Of Esophagus 29Cholangiocarcinoma 28Carcinoma, Hepatocellular 26Adenocarcinoma 26Biliary Tract Neoplasms 23Lymphoma, Large B-Cell, Diffuse 19Recurrence 17Carcinoma, Non-Small-Cell Lung 16Gallbladder Neoplasms 14Breast Neoplasms 14Head and Neck Neoplasms 11Locally Advanced Rectal Cancer 10Liver Neoplasms 10Gastrointestinal Neoplasms 10Esophageal Squamous Cell Carcinoma 9Peritoneal Neoplasms 8Ovarian Neoplasms 8Colorectal Cancer Metastatic 7Bile Duct Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Extranodal NK-T-Cell 5

Interventions

STA 9090 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophagogastric Cancer × Oxaliplatin × Clear all
NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡